Our senior leaders bring a powerful combination of proven commercial, strategic and scientific capabilities
Our Executive Team
Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our chief executive officer and member of the board of directors since June 2021 and had served as president and interim chief executive officer from February 2021 to June 2021. Mr. McCourt had served as president from April 2019 to June 2021. Prior to April 2019, Mr. McCourt had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009.
Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®.
Mr. McCourt serves on the board of directors and as a member of the compensation committee of Pliant Therapeutics, Inc. (Nasdaq: PLRX) and on the board of trustees for the American Society of Gastrointestinal Endoscopy (ASGE). Mr. McCourt recently served on the board of directors of Acceleron Pharma Inc., serving as Chairman of the Nomination and Governance committee and as a member of the Audit and Compensation committees. He also recently received the 2023 PM360 Uber ELITE Award, the 2022 ASGE President’s Award and was featured in PharmaVoice sharing his strategy and vision for the company. Mr. McCourt holds a degree in pharmacy from the University of Wisconsin.
Michael Shetzline, M.D., Ph.D.
Dr. Shetzline has served as our chief medical officer, and head of research and drug development since October 2021 and had served as chief medical officer, and head of drug development from January 2019 to October 2021. Dr. Shetzline is a gastroenterologist and internist, with more than 25 years of experience in the biopharmaceutical industry and academia. Before joining Ironwood, Dr. Shetzline was vice president and head of gastroenterology clinical sciences at Takeda Pharmaceuticals International Co., or Takeda, a global pharmaceutical company, where he led global clinical development for all GI assets from January 2015 to January 2019. Prior to Dr. Shetzline’s role at Takeda, Dr. Shetzline served as vice president and global head of gastroenterology at Ferring International Pharmascience Center U.S., Inc., or Ferring, from 2012 to January 2015, during which he led Ferring’s clinical development programs in gastroenterology. Before that, Dr. Shetzline was vice president and global program head crossing multiple therapeutic areas and head of translational medicine GI discovery at Novartis Pharmaceuticals AG from 2002 to 2012. Dr. Shetzline also served as gastroenterology program director and assistant professor of medicine at Duke University Medical Center from 1997 to 2002. Dr. Shetzline has published over 40 full papers and book chapters and acted as a reviewer for a range of medicine journals. Dr. Shetzline earned his M.D. and Ph.D. from The Ohio State University in physiology and medicine. Dr. Shetzline completed his internal medicine residency and fellowship in gastroenterology and served on the faculty as a National Institutes of Health supported physician scientist at Duke University Medical Center. Dr. Shetzline is a Fellow of the American College of Physicians, the American College of Gastroenterology, and the American Gastroenterological Association and certified by the American Board of Internal Medicine.
Susanna Y. Huh, MD, MPH
Dr. Huh has served as Vice President and Head of Clinical Development since September 2022. Dr. Huh is a board-certified pediatric gastroenterologist experienced leader in clinical development, clinical and epidemiologic research, and quality improvement. Before joining Ironwood, Dr. Huh was Senior Medical Director and Global Clinical Lead in the gastrointestinal therapeutic area unit at Takeda Pharmaceuticals, where she led global clinical development for the TAU’s microbiome portfolio, overseeing the clinical strategy for inflammatory bowel disease and liver disease assets in preclinical through Phase 2. Prior to this role, Dr. Huh held clinical development leadership roles in asset programs across phases 1-4 targeting motility, inflammatory bowel disease, and rare pediatric disease.
Dr. Huh is an accomplished clinician and researcher who is Assistant Professor of Pediatrics at Harvard Medical School and a Pediatric Gastroenterologist at Boston Children’s Hospital. Prior to joining Takeda Pharmaceuticals, Dr. Huh’s clinical and research interests focused on the effects of early childhood nutrition on lifelong health. For ten years, Dr. Huh directed the Growth and Nutrition Program, a multidisciplinary program offering diagnosis and treatment for children with malnutrition and feeding difficulties, and she continues a part-time clinical practice in this program. She has held NIH and other research grants, and her research on prenatal and early childhood factors associated with child obesity have earned national media attention.
Dr. Huh has over 20 published research articles and has served as an ad hoc reviewer for multiple journals, including New England Journal of Medicine and The Journal of the American Medical Association (JAMA). She has been a speaker at multiple national and international meetings. She has received mentoring awards, including the Women in the Enterprise of Science and Technology and the David S. Weiner award for leadership and innovation in child health from Boston Children’s Hospital. Dr. Huh earned her M.D. from Western University (Ontario, Canada) and MPH from Harvard T.H. Chan School of Public Health, concentrating on clinical effectiveness. Dr. Huh completed her residency at the Children’s Hospital of Western Ontario and did her fellowship in pediatric gastroenterology and nutrition at Boston Children’s Hospital and Harvard Medical School. She is a member of the advisory boards for Women in the Enterprise of Science and Technology (WEST) and Mother’s Milk Bank Northeast.
Sravan K. Emany
Mr. Emany has served as our chief financial officer since December 2021. Prior to joining Ironwood, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company, since March 2020 and as vice president of strategy, treasury and investor relations from February 2018 to March 2020. Prior to that, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the board of directors of Assertio Holdings, Inc. (Nasdaq: ASRT). Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.
Diane Stroehmann is Vice President of Regulatory Affairs and Global Patient Safety at Ironwood. Prior to joining the company in August 2019, Ms. Stroehmann was Chief of Staff to the CEO and Head of Regulatory Affairs and Quality at Sienna Pharmaceuticals from 2016 to 2019. Prior to Sienna, Ms. Stroehmann was Vice President of Regulatory Affairs, Pharmacovigilance and Research Compliance at Kythera Biopharmaceuticals from September 2013 to October 2015 when it was acquired by Allergan. At Kythera, Ms. Stroehmann led the successful submission and approval of Kybella® in the U.S. and Canada in addition to the submission of multiple international marketing applications. She also had oversight for FDA Advisory Committee preparations for Kybella which led to a unanimous vote in favor of approval. Ms. Stroehmann was Head of Regulatory Affairs at Medicis Pharmaceutical Corporation where she worked for nearly ten years. Over the course of her career, Ms. Stroehmann has amassed experience in all phases of pharmaceutical development – from discovery through clinical development to marketing approval. She played a critical role in multiple NDAs, BLAs, and PMAs at Medicis that eventually led to successful product approvals in dermatology and aesthetic medicine, including Solodyn®, Vanos®, Dysport®, and Restylane®. She has worked on drug products in a variety of therapeutic areas including the development of pharmaceutical therapies via the company’s orphan drug subsidiary, Ucyclyd Pharma. Ms. Stroehmann earned a B.S. in biology at the University of Illinois Urbana-Champaign and an M.S. in regulatory affairs from San Diego State University.
Mr. Minardo has served as our chief legal officer since August 2021. Prior to joining Ironwood, Mr. Minardo was with Seqirus, a pharmaceutical company, where he was vice president, general counsel and a member of the Seqirus executive leadership team, leading a global legal team overseeing activities including business transactions, regulatory matters, corporate governance, compliance and intellectual property from November 2015 to July 2021. Prior to Seqirus, Mr. Minardo was with Novartis in increasing roles of responsibility from October 2007 to November 2015, ultimately serving as vice president, general counsel and chief compliance officer at Novartis Influenza Vaccines. Mr. Minardo started his legal career as a litigator at Kaye Scholer LLP. Mr. Minardo holds a B.A. from Boston College and a J.D. from Brooklyn Law School.
Tammi Gaskins is Vice President of Brand Management at Ironwood. She joined the company in July 2020 as Senior Director of Marketing. Prior to joining Ironwood, Ms. Gaskins spent over 20 years at AstraZeneca, most recently serving as Executive Director of the Diabetes Franchise. She also held positions of increasing seniority within the company’s Specialty and Primary Care Brands and spent time in Dubai as Commercial Director for the Middle East Area. Ms. Gaskins received a B.A. in international studies from Trinity College in Washington, D.C.
Mr. Davis has served as our chief business officer since December 2021 and had served as senior vice president of corporate development, strategy and valuation from May 2021 to December 2021. Before joining Ironwood, Mr. Davis served as the chief business development and M&A officer at iNova Pharmaceuticals from September 2017 to May 2021, leading all company transactions and acting as a member of the executive management team. Prior to iNova, Mr. Davis was head of oncology business development for Merck & Co. from November 2016 to September 2017. Before his time at Merck, Mr. Davis was at Bausch Health Companies (formerly Valeant Pharmaceuticals), where he held roles of increasing responsibility within the business development function, ultimately serving as senior vice president of business development and leading all transactions for the company, including the acquisitions of Salix Pharmaceuticals and Bausch + Lomb. Mr. Davis began his career as an analyst at McKinsey & Co., where his work focused on the healthcare space. Mr. Davis serves on the board of directors of Biomarck Pharmaceuticals, Ltd. and UTILITY therapeutics Ltd. Mr. Davis holds a B.A. in economics from Boston University.
Beth Calitri joined Ironwood Pharmaceuticals in 2019. Ms. Calitri has spent more than 25 years in healthcare communications working at a host of major U.S. and international pharmaceutical companies, as well as leading communications agencies. Currently, she leads corporate communications and media relations at Ironwood Pharmaceuticals where she infuses energy, purpose, and collaboration into her work to tell the company’s story as a leader in the gastrointestinal (GI) pharmaceutical space. Ms. Calitri believes that all effective communications start with compelling storytelling and is proud to serve as Ironwood Pharmaceuticals’ chief storyteller.
Ms. Calitri’s extensive experience as a team leader and communicator, as well as her focus on driving businesses forward, have helped propel companies to achieve their goals and create committed, purpose-driven workplace cultures. Ms. Calitri is an advocate of authentic employee engagement, patient-focused communications, and creating workplace cultures that are based on values and ethics.
Before joining Ironwood Pharmaceuticals, Ms. Calitri used her deep expertise in corporate and brand communications, media relations, issues management, employee engagement and narrative building to help companies as Head of R&D Site Communications at Pfizer, Deputy Head of Global Media Relations at Novartis and part of the Brand Communications team at AstraZeneca, tell their stories in impactful and meaningful ways. Her experience in the GI space includes leading communications for blockbuster drugs such as Nexium, Zelnorm and Prilosec. While at Novartis, she was a founding team member of the vaccines division where she played a critical role in global communications and crisis management around the H1N1 virus. She was a member of the company’s Americas management committee and later, Deputy Head of Global Media Relations.
Ms. Calitri is on the advisory board of the Harrington School of Communication and Media at the University of Rhode Island where she graduated with a B.A. in Communications and Public Relations. She also serves on the advisory board for WEST – Women in the Enterprise of Science and Technology. She earned a degree in Spanish Studies at the Universidad de Salamanca in Spain and studied nutrition and chemistry at Hunter College, New York. She has lived and worked internationally, including the UK and Switzerland.
Mike Nanfito is Vice President of Sales and Sales Excellence at Ironwood. He joined the company in May 2012 as Executive Regional Sales Manager and became Vice President of Field Sales in 2016. Prior to joining Ironwood, Mr. Nanfito was most recently Managing Director at Novartis where he also held various sales and marketing positions spanning 18 years. From 2005 to 2009, Mr. Nanfito was Director of Marketing at Amgen. Mr. Nanfito earned a B.S. in operations management and an M.B.A. from California State Polytechnic University-Pomona.
Marcel Moulaison is Vice President of Technical Operations at Ironwood. In this role he leads Ironwood’s supply chain, manufacturing, CMC development, and quality functions. He joined the company in 2014 as Vice President of Quality. Prior to joining Ironwood, Mr. Moulaison held various quality–related roles of increasing seniority in his nearly 20 years at Sunovion Pharmaceuticals Inc. (formerly Sepracor Pharmaceuticals). These roles culminated in his service as Executive Director, Quality Operations, where he oversaw all R&D and commercial pharmaceutical products from 2011 to 2014. Mr. Moulaison received a B.S. in chemistry from Dalhousie University.
Ms. Jana Noeldeke is Basel Site Head and Vice President of Apraglutide Life Cycle Leadership at Ironwood. Prior to joining the company in June 2023 through the acquisition of VectivBio, Ms. Noeldeke was Vice President, Life Cycle Leadership, with VectivBio. Before joining VectivBio, she served as Life Cycle Leader at Roche, leading cross-functional teams responsible for the development and commercialization of several late-stage assets in the Respiratory and Immunology disease areas and for a late-stage development compound for the treatment of Autism Spectrum Disorder. From 2016 to 2018, Ms. Noeldeke was Senior Director and Project Champion CNS and Pain with Teva Pharmaceuticals. Ms. Noeldeke began her career at Roche, where she held roles of increasing responsibility, ultimately serving as Head Project Team Leader NORD (Neuroscience, Ophthalmology, Rare Diseases). Ms. Noeldeke brings nearly 30 years of experience in the pharmaceutical industry across a range of therapeutic areas, including nearly 20 years in drug development as project and team leader. Ms. Noeldeke earned her Ph.D. in 2005 from Humboldt University of Berlin. She holds a M.Sc. in Biology from Free University of Berlin.
Our highly experienced and diverse board is instrumental in creating shareholder value
Our Board of Directors
Julie McHugh joined our board of directors in February 2014 and became chair of our board in April 2019. Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc. Before that she served as company group chairman for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), Evelo Biosciences, Inc. (Nasdaq: EVLO), and Xellia Pharmaceuticals ApS. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute. Ms. McHugh received her M.B.A. degree from St. Joseph’s University and her B.S. degree from Pennsylvania State University.
Mark Currie, Ph.D.
Mark Currie, Ph.D.
Mark Currie joined our board of directors in April 2019. Dr. Currie has been the chair of the scientific advisory board of Cyclerion Therapeutics, Inc., or Cyclerion, a clinical-stage biopharmaceutical company, since January 2021. Dr. Currie previously served as Cyclerion’s president and chief scientific officer from April 2019 to December 2020. Prior to joining Cyclerion, Dr. Currie served as senior vice president, chief scientific officer and president of research and development at Ironwood from 2002 to April 2019. Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc. and initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie currently serves on the board of directors of Science Exchange, Inc. and Sea Pharmaceuticals, LLC, privately held companies. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman Gray School of Medicine of Wake Forest University.
Alexander Denner, Ph.D.
Alexander Denner, Ph.D.
Alexander Denner joined our board of directors in October 2020. Dr. Denner is the founding partner and the chief investment officer of Sarissa Capital Management LP, or Sarissa, a registered investment advisor, where he has been since 2011. Dr. Denner served as chairman and chief executive officer of Sarissa Capital Acquisition Corp., a special purpose acquisition company from September 2020 to December 2022. Prior to joining Sarissa, Dr. Denner served as a senior managing director at Icahn Capital L.P, an investment advisory firm, from 2006 to 2011. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm. Dr. Denner serves on the board of directors of Attralus, Inc. In the last five years, Dr. Denner has served as chair of the board of directors of The Medicines Company and Sarissa Capital Acquisition Corp., as well as a member of the board of directors of Biogen Inc. and Bioverativ Inc. Dr. Denner earned his B.S. in mechanical engineering from Massachusetts Institute of Technology, an M.S. and M.Phil. in mechanical engineering from Yale University and an interdisciplinary Ph.D. from Yale University.
Andrew Dreyfus joined our board of directors in April 2016. Mr. Dreyfus most recently served as president and chief executive officer for Blue Cross Blue Shield of Massachusetts, or BCBSMA, one of the largest Blue Cross Blue Shield insurance plans in the country from 2010 to 2022. From 2005 to 2010, Mr. Dreyfus served as the executive vice president of healthcare services of BCBSMA. Prior to joining BCBSMA, he served as the first president of the Blue Cross Blue Shield Foundation. Mr. Dreyfus also previously served as executive vice president of the Massachusetts Hospital Association and held a number of senior positions in Massachusetts state government, including undersecretary of consumer affairs and business regulation. Mr. Dreyfus serves on the board of directors of the Joint Commission and BCBSMA Foundation, both non-profit organizations and on Alto Neuroscience, Inc., a privately held company. He is a member of the advisory boards of Ariadne Labs, Vanna Health and Massachusetts Coalition for Serious Illness Care. He previously served on the board of directors for BCBSMA, the Blue Cross Blue Shield Associated and RIZE Massachusetts. Mr. Dreyfus received a B.A. in English from Connecticut College.
Jon Duane joined our board of directors in April 2019. Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey, an international management consulting company. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. In that role, Mr. Duane advised both private and public companies in the pharmaceutical, medical device and life science industries, as well as academic research centers, on various strategic initiatives. Mr. Duane serves as the executive chair on the board of directors of Nashville Biosciences, LLC. Mr. Duane graduated from Wesleyan University with a B.A. in government and received an M.B.A from Harvard Business School.
Marla Kessler joined our board of directors in April 2019. Ms. Kessler has been chief marketing officer of Datavant, Inc., or Datavant, a health IT company, since October 2022. Prior to joining Datavant, Ms. Kessler served as chief customer officer of Aetion, Inc., or Aetion, a health care technology company, from September 2021 to October 2022, and prior to that, served as an advisor to the chief executive officer of IQVIA Holdings Inc., or IQVIA (formerly IMS Health and Quintiles), a global analytics and technology company, from October 2020 to February 2021. Prior to that, Ms. Kessler had been the senior vice president for strategy, marketing and communications for IQVIA since October 2016. Previously, Ms. Kessler served in various roles for IQVIA, including vice president for global services marketing and knowledge management from 2013 to September 2016, regional leader of the IMS Consulting Group in Europe from 2011 to 2013, location manager for the London IMS Consulting Group from 2009 to 2011 and senior principal from 2008 to 2009. Before joining IQVIA, Ms. Kessler led several marketing efforts for Pfizer Inc. from 2004 to 2007 and worked in consulting for McKinsey & Company from 1996 to 2004. Ms. Kessler received a B.S. in economics from Arizona State University and an M.B.A. from the Fuqua School of Business at Duke University.
Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our chief executive officer and member of the board of directors since June 2021 and had served as president and interim chief executive officer from February 2021 to June 2021. Mr. McCourt had served as president from April 2019 to June 2021. Prior to April 2019, Mr. McCourt had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®. Mr. McCourt recently served on the board of directors of Acceleron Pharma Inc., serving as Chairman of the Nomination and Governance committee and as a member of the Audit and Compensation committees. He holds a degree in pharmacy from the University of Wisconsin.
Catherine Moukheibir joined our board of directors in April 2019. Ms. Moukheibir most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chairman of the board of directors of MedDay from April 2016 to January 2021. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. Ms. Moukheibir currently serves on the board of directors of MoonLake Immunotherapeutics AG (Nasdaq: MLTX), Biotalys NV (EBR: BTLS), Oxford Biomedica plc (LSE: OXB), Asceneuron SA, Noema Pharma AG, DNA Script SAS, and CMR Surgical. She held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA, Creabilis S.A., GenKyoTex S.A., Kymab Group Limited, Orphazyme A/S and Zealand Pharma A/S. Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.
Jay P. Shepard
Jay P. Shepard
Jay Shepard joined our board of directors in December 2020. Mr. Shepard is an advisor at Caralys Pacific, a venture group focused on licensing drug programs and creating new companies in the U.S. and Japan.
Mr. Shepard previously was president and chief executive officer of Aravive, Inc. (formerly Versartis, Inc.), a clinical-stage oncology company, from May 2015 to January 2020, when he retired. From 2013 to 2015, Mr. Shepard was executive chairman of Versartis, Inc. From 2008 until May 2015, Mr. Shepard was an executive partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry. From 2010 to 2012, Mr. Shepard served as president and chief executive officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pediatric pharmaceutical company. From 2005 to 2007, Mr. Shepard served as interim president and chief executive officer of Relypsa (Ilypsa, Inc.’s spin-out company, which was acquired by Galencia), a pharmaceutical company. Mr. Shepard was also vice president of commercial operations at Telik and oncology business unit head of Alza Pharmaceuticals (acquired by J&J). Mr. Shepard has over 35 years of experience in the pharmaceutical, biotechnology and drug delivery arenas. Mr. Shepard has participated in or led over 16 product launches by preparing markets and establishing sales and marketing operations. Mr. Shepard also currently serves on the board of directors of Inovio Pharmaceuticals, Inc. (Nasdaq: INO), Esperion Therapeutics, Inc. (Nasdaq: ESPR), Aculys Pharma, LLC, Cessation Therapeutics, LLC and Pathalys Pharma, Inc. Mr. Shepard also serves as the chairman of the board of directors of the Christopher & Dana Reeve Foundation. Within the past five years, Mr. Shepard also served on the boards of directors of Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.